Appointed industry veteran, David Webster, as new Chief Commercial Officer Recently upgraded LungFit PH device expands customer base; revenue growth […]
Results from the CATALYST clinical trial were presented at the American Diabetes Association’s 84thScientific Sessions at a featured plenary session […]
Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by […]